Cardiol Therapeutics Inc.
NASDAQ:CRDLDrug Manufacturers - Specialty & Generic
-$0.01 today
- Market cap
- $114.64M
- Beta
- 0.80
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.33
Volume 0.31M
Average 0.68M
CRDL Debt Repayment
Cash used to repay borrowings during the period.
Cardiol Therapeutics Inc.NASDAQ: CRDL
Debt Repayment · Q1 FY2026 · quarter ended Mar 2026
Debt repayment grows, but more slowly than its trailing trend
Q1 FY2026 debt repayment of CA$13.84K (cash outflow) rose 0.0% year over year, behind the +33.3% change in trailing-twelve-month debt repayment. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +0.9% a year.
Context
- Debt repayment grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +0.0% toward the trailing-twelve-month pace of +33.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
CAD · from the cash flow
- Latest · FY2025
- (55.38K) CAD
- Year-over-year change
- -33.3%
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (55.38K) | -33.3% |
| FY2024 | 2024-12-31 | (41.53K) | +25.0% |
| FY2023 | 2023-12-31 | (55.38K) | -2.7% |
| FY2022 | 2022-12-31 | (53.93K) | -3.9% |
| FY2021 | 2021-12-31 | (51.92K) | — |
Debt Repayment vs competitors
How CRDL compares with its peers on the latest reported figures
- Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +33.3% is the 2nd highest of 3, against a peer median of +28.0%.
- Over three fiscal years its annual growth of +0.9% compares with a peer median of -0.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
IMAImageneBio Inc | LTM Mar 2026 | $15M USD | — | — | — |
| LTM Mar 2026 | $13.64M USD | — | — | 89.0% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $7.5M USD | — | +20.4% | — |
| LTM Mar 2026 | $141K USD | -50.4% | -88.9% | — | |
| LTM Mar 2026 | CA$55.38K CAD | +33.3% | +0.9% | — | |
| LTM Mar 2026 | €25.41K EUR | +106.3% | -0.6% | 86.6% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2025 | ₪0 ILS | — | — | 0.0% | |
| FY2025 | $0 USD | — | — | 0.0% | |
| Peer median (excluding CRDL) | — | +28.0% | -0.6% | 0.0% | |
Competitors are the stored peer set for CRDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (31.64M) | (30.93M) | (28.13M) | (36.68M) | (33.82M) |
| Depreciation & Amortization | 220.42K | 219.91K | 248.36K | 373.11K | 101.98K |
| Deferred Income Tax | (4.92M) | (9.16M) | 0 | 0 | 0 |
| Stock-Based Compensation | 8.5M | 5.01M | 4.16M | 14.28M | 10.7M |
| Change in Working Capital | 76.52K | 5.75M | (545.88K) | (931.57K) | (733.34K) |
| Accounts Receivables | (59.95K) | (144.18K) | 200.33K | (81.75K) | 135.43K |
| Inventory | 17.97K | (4.47M) | 0 | 0 | 0 |
| Accounts Payables | 2.39M | 4.47M | 0 | 0 | 0 |
| Other Working Capital | (2.27M) | 5.89M | (746.2K) | (849.82K) | (868.76K) |
| Other Non-Cash Items | 4.21M | 1.89M | (911.39K) | (2.1M) | (105.34K) |
| Operating Cash Flow | (23.55M) | (27.22M) | (25.18M) | (25.06M) | (23.85M) |
| Capital Expenditures | (12.92K) | (74.71K) | (64.31K) | (21.29K) | (24.48K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (12.92K) | (74.71K) | (64.31K) | (21.29K) | (24.48K) |
| Debt Repayment | (51.92K) | (53.93K) | (55.38K) | (41.53K) | (55.38K) |
| Common Stock Issued | 84.08M | 0 | 0 | 21.36M | 16.07M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.41M | (0) | 0 | (2.47M) | (477.03K) |
| Financing Cash Flow | 93.44M | (53.93K) | (55.38K) | 18.84M | 15.54M |
| Effect of Forex Changes | (11.13K) | 2.92M | 762.04K | 1.89M | (824.04K) |
| Net Change in Cash | 69.87M | (24.43M) | (24.54M) | (4.35M) | (9.16M) |
| Free Cash Flow | (23.56M) | (27.3M) | (25.24M) | (25.08M) | (23.88M) |
Cardiol Therapeutics Inc.
NASDAQ:CRDL
Intrinsic Alpha fair value
Locked
Current Price
$0.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.